Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions

NC. Venn, L. Huang, L. Hovorková, W. Muskovic, M. Wong, T. Law, SL. Heatley, SL. Khaw, T. Revesz, L. Dalla Pozza, PJ. Shaw, C. Fraser, AS. Moore, S. Cross, K. Bendak, MD. Norris, MJ. Henderson, DL. White, MJ. Cowley, TN. Trahair, J. Zuna, R. Sutton

. 2022 ; 127 (5) : 908-915. [pub] 20220601

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024523
E-zdroje Online Plný text

NLK Free Medical Journals od 1947 do Před 1 rokem
Freely Accessible Journals od 1947 do Před 1 rokem
PubMed Central od 1947 do Před 1 rokem
Europe PubMed Central od 1947 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1947-01-01
Open Access Digital Library od 1999-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 35650277
DOI 10.1038/s41416-022-01806-6
Knihovny.cz E-zdroje

BACKGROUND: ABL-class fusions including NUP214-ABL1 and EBF1-PDGFRB occur in high risk acute lymphoblastic leukaemia (ALL) with gene expression patterns similar to BCR-ABL-positive ALL. Our aim was to evaluate new DNA-based measurable residual disease (MRD) tests detecting these fusions and IKZF1-deletions in comparison with conventional immunoglobulin/T-cell receptor (Ig/TCR) markers. METHODS: Precise genomic breakpoints were defined from targeted or whole genome next generation sequencing for ABL-fusions and BCR-ABL1. Quantitative PCR assays were designed and used to re-measure MRD in remission bone marrow samples previously tested using Ig/TCR markers. All MRD testing complied with EuroMRD guidelines. RESULTS: ABL-class patients had 46% 5year event-free survival and 79% 5year overall survival. All had sensitive fusion tests giving high concordance between Ig/TCR and ABL-class fusion results (21 patients, n = 257 samples, r2 = 0.9786, P < 0.0001) and Ig/TCR and IKZF1-deletion results (9 patients, n = 143 samples, r2 = 0.9661, P < 0.0001). In contrast, in BCR-ABL1 patients, Ig/TCR and BCR-ABL1 tests were discordant in 32% (40 patients, n = 346 samples, r2 = 0.4703, P < 0.0001) and IKZF1-deletion results were closer to Ig/TCR (25 patients, n = 176, r2 = 0.8631, P < 0.0001). CONCLUSIONS: MRD monitoring based on patient-specific assays detecting gene fusions or recurrent assays for IKZF1-deletions is feasible and provides good alternatives to Ig/TCR tests to monitor MRD in ABL-class ALL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024523
003      
CZ-PrNML
005      
20221031100108.0
007      
ta
008      
221017s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41416-022-01806-6 $2 doi
035    __
$a (PubMed)35650277
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Venn, Nicola C $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
245    10
$a Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions / $c NC. Venn, L. Huang, L. Hovorková, W. Muskovic, M. Wong, T. Law, SL. Heatley, SL. Khaw, T. Revesz, L. Dalla Pozza, PJ. Shaw, C. Fraser, AS. Moore, S. Cross, K. Bendak, MD. Norris, MJ. Henderson, DL. White, MJ. Cowley, TN. Trahair, J. Zuna, R. Sutton
520    9_
$a BACKGROUND: ABL-class fusions including NUP214-ABL1 and EBF1-PDGFRB occur in high risk acute lymphoblastic leukaemia (ALL) with gene expression patterns similar to BCR-ABL-positive ALL. Our aim was to evaluate new DNA-based measurable residual disease (MRD) tests detecting these fusions and IKZF1-deletions in comparison with conventional immunoglobulin/T-cell receptor (Ig/TCR) markers. METHODS: Precise genomic breakpoints were defined from targeted or whole genome next generation sequencing for ABL-fusions and BCR-ABL1. Quantitative PCR assays were designed and used to re-measure MRD in remission bone marrow samples previously tested using Ig/TCR markers. All MRD testing complied with EuroMRD guidelines. RESULTS: ABL-class patients had 46% 5year event-free survival and 79% 5year overall survival. All had sensitive fusion tests giving high concordance between Ig/TCR and ABL-class fusion results (21 patients, n = 257 samples, r2 = 0.9786, P < 0.0001) and Ig/TCR and IKZF1-deletion results (9 patients, n = 143 samples, r2 = 0.9661, P < 0.0001). In contrast, in BCR-ABL1 patients, Ig/TCR and BCR-ABL1 tests were discordant in 32% (40 patients, n = 346 samples, r2 = 0.4703, P < 0.0001) and IKZF1-deletion results were closer to Ig/TCR (25 patients, n = 176, r2 = 0.8631, P < 0.0001). CONCLUSIONS: MRD monitoring based on patient-specific assays detecting gene fusions or recurrent assays for IKZF1-deletions is feasible and provides good alternatives to Ig/TCR tests to monitor MRD in ABL-class ALL.
650    _2
$a dítě $7 D002648
650    12
$a bcr-abl fúzní proteiny $x genetika $7 D016044
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobuliny $7 D007136
650    _2
$a reziduální nádor $x genetika $7 D018365
650    12
$a akutní lymfatická leukemie $x genetika $7 D054198
650    _2
$a receptory antigenů T-buněk $x genetika $7 D011948
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Huang, Libby $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
700    1_
$a Hovorková, Lenka $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u CLIP-Childhood Leukaemia Investigation Prague, Prague, Czech Republic
700    1_
$a Muskovic, Walter $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
700    1_
$a Wong, Marie $u Computational Biology, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
700    1_
$a Law, Tamara $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
700    1_
$a Heatley, Susan L $u Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia $u School of Medicine, University of Adelaide, Adelaide, SA, Australia $1 https://orcid.org/0000000174976477
700    1_
$a Khaw, Seong Lin $u Children's Cancer Centre, The Royal Children's Hospital, Melbourne, VIC, Australia
700    1_
$a Revesz, Tom $u School of Medicine, University of Adelaide, Adelaide, SA, Australia $u Department of Clinical Haematology and Oncology, Women's and Children's Hospital, Adelaide, SA, Australia
700    1_
$a Dalla Pozza, Luciano $u Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia
700    1_
$a Shaw, Peter J $u Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, NSW, Australia
700    1_
$a Fraser, Chris $u Blood and Bone Marrow Transplant Program, Queensland Children's Hospital, Brisbane, QLD, Australia
700    1_
$a Moore, Andrew S $u Paediatric Oncology, Queensland Children's Hospital, Brisbane, QLD, Australia $1 https://orcid.org/0000000180621779
700    1_
$a Cross, Siobhan $u Children's Haematology/Oncology Centre Christchurch Hospital, Christchurch, New Zealand $1 https://orcid.org/0000000231039763
700    1_
$a Bendak, Katerina $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
700    1_
$a Norris, Murray D $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia $u School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia $1 https://orcid.org/0000000206324589
700    1_
$a Henderson, Michelle J $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia $u School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia $1 https://orcid.org/0000000327413852
700    1_
$a White, Deborah L $u Precision Medicine Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia $u School of Medicine, University of Adelaide, Adelaide, SA, Australia $1 https://orcid.org/000000034844333X
700    1_
$a Cowley, Mark J $u Computational Biology, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia $u School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia $1 https://orcid.org/0000000295195714
700    1_
$a Trahair, Toby N $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia $u School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia $u Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia $1 https://orcid.org/000000023295228X
700    1_
$a Zuna, Jan $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u CLIP-Childhood Leukaemia Investigation Prague, Prague, Czech Republic $u University Hospital Motol, Prague, Czech Republic
700    1_
$a Sutton, Rosemary $u Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia. rsutton@ccia.unsw.edu.au $u School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia. rsutton@ccia.unsw.edu.au $1 https://orcid.org/0000000201886005
773    0_
$w MED00009369 $t British journal of cancer $x 1532-1827 $g Roč. 127, č. 5 (2022), s. 908-915
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35650277 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100106 $b ABA008
999    __
$a ok $b bmc $g 1854315 $s 1175813
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 127 $c 5 $d 908-915 $e 20220601 $i 1532-1827 $m British journal of cancer $n Br J Cancer $x MED00009369
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace